Report of the International Consensus Development Conference on Female Sexual Dysfunction: Definitions and Classifications

Basson, Rosemary; Berman, Jennifer R.; Burnett, Arthur L.; Derogatis, Leonard R.; Ferguson, David M.; Fourcroy, Jean L.; Goldstein, Irwin; Graziottin, Alessandra; Heiman, Julia R.; Laan, Ellen; Leiblum, Sandra R.; Padma‐Nathan, Harin; Rosen, Raymond C.; Segraves, K. B.; Segraves, Robert; Shabsigh, Ridwan; Sipski, Marcalee; Wagner, Gorm; Whipple, Beverly

doi:10.1080/00926230152051707

Cited by 465 publications

(665 citation statements)

References 12 publications

Supporting

Mentioning

583

Contrasting

Unclassified

Order By: Relevance

“…This questionnaire requires less explicit sexual descriptions than other questionnaires and helps subjects reveal their sex life without being provoked. 14,15 In addition, the FSFI has a verified numeric rating scale system, enabling investigators to easily determine any improvement in sexual function.…”

Section: Discussionmentioning

confidence: 99%

Influence of weight reduction by sibutramine on female sexual function

et al. 2006

View full text Add to dashboard Cite

Background: It is well known that selective serotonin reuptake inhibitors (SSRIs) can cause sexual dysfunction, so it is possible that sibutramine, a serotonin and norepinephrine reuptake inhibitor, could induce sexual dysfunction. Design and subjects: The effect of sibutramine on sexual function was evaluated in 46 overweight and obese (body mass index (BMI) X23 kg/m 2 ) but otherwise healthy married women (28-44 years). Participants were randomly assigned at baseline to either the sibutramine or control group. The Female Sexual Function Index (FSFI) questionnaire was used to assess sexual function at baseline and after treatment with behavioral therapy plus sibutramine 10 mg once daily or behavioral therapy alone (control) for 8 weeks.Results: Mean weight loss from baseline to week 8 was À6.03% in sibutramine group and À0.38% in the control group. There was significant improvement of FSFI total score, arousal domain score and lubrication domain score in the sibutramine group (Po0.05), and significant differences in arousal, orgasm, satisfaction domain score and total score (Po0.05) in favor of sibutramine. Decreases in body weight and BMI were correlated with the improvement of arousal (r ¼ À0.44 and r ¼ À0.48, respectively) and orgasm (r ¼ À0.45 and r ¼ À0.46, respectively) domains. Conclusion: Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women. The degree of improvement in sexual function was correlated with the degree of weight reduction.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of weight reduction by sibutramine on female sexual function

et al. 2006

View full text Add to dashboard Cite

show abstract

“…50 Sexual difficulties in women appear to be widespread in society, influenced by both healthrelated and psychosocial factors, and are associated with impaired quality of life and interpersonal relationships. 51 Older data reveal that up to 76% of women had some type of sexual dysfunction.…”

Section: Obesity Metabolic Syndrome and Female Sexual Functionmentioning

confidence: 99%

Obesity and sexual dysfunction, male and female

et al. 2008

View full text Add to dashboard Cite

Obesity has become a worldwide public health problem of epidemic proportions, as it may decrease life expectancy by 7 years at the age of 40 years: excess bodyweight is now the sixth most important risk factor contributing to the overall burden of disease worldwide. Overweight and obesity may increase the risk of erectile dysfunction (ED) by 30-90% as compared with normal weight subjects. On the other hand, subjects with ED tend to be heavier and with a greater waist than subjects without ED, and also are more likely to be hypertensive and hypercholesterolemic. The metabolic syndrome, characterized by a clustering of risk factors associated with insulin resistance and abdominal obesity, associates with ED. Moreover, women with the metabolic syndrome have an increased prevalence of sexual dysfunctions as compared with matched control women. Lifestyle changes aimed at reducing body weight and increasing physical activity induce amelioration of both erectile and endothelial functions in obese men. Moreover, preliminary evidence suggests that a Mediterranean-style diet might be effective in ameliorating sexual function in women with the metabolic syndrome. Lifestyle changes, mainly focussing on regular physical activity and a healthy diet, are effective and safe ways to reduce cardiovascular diseases and premature mortality in all population groups; they may also prevent and treat sexual dysfunctions in both sexes.

show abstract

“…It includes disorders of desire/libido, arousal, inhibited orgasm, and sexual pain (81). Prevalence increases with age, cardiovascular disease, diabetes, cancer, hysterectomy, and neurological conditions (38,82).…”

Section: Female Sexual Dysfunctionmentioning

confidence: 99%